PerMIT:Warfarin is a decision support tool driven by a set of algorithms. The software provides a graphic display of historical and projected aspects of treatment, allowing a more proactive approach to managing care. It analyzes genetic and other patient data to provide information physicians can immediately apply in the dosing and monitoring of warfarin, a commonly prescribed anticoagulant.
In normal practice, warfarin patients require numerous office visits and blood tests to detect and prevent adverse drug reactions (ADRs), which can include internal bleeding, thrombosis and death. To prevent those ADRs, the dosage is adjusted and blood tests taken in a gradual, iterative process that can take months to reach stable therapy.
A previous pilot study conducted by PGXL and published in Thrombosis and Haemostasis showed that patients treated using PerMIT:Warfarin reached therapeutic stability in a shorter time than those treated conventionally.
"This larger study goes a step farther," says Dr.
PerMIT:Warfarin calculates an optimal therapeutic path based on variations in two genes, CYP2C9 and VKORC1, which control the metabolism and action of the drug. The software may enable physicians to avoid the pitfalls of standardized dosing regimens and calculate tailored dosing strategies to minimize variability and time to reach stable therapy.
PGXL is recruiting sites for the new study. Investigators are welcome to contact the company if they are interested in access to the software or participating in the trials. Previous studies were conducted at the
Along with its clinical practice, PGXL performs contract research for developers of pharmaceuticals and medical devices.
Keywords for this news article include: Adverse Drug Reaction, Anticoagulants, Clinical Trials and Studies, Drug Toxicity, Drugs, Genetics,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- U.S. Families 'Extraordinarily Vulnerable': Yellen
- Larry Ellison Steps Down as Oracle CEO
- Hillary Clinton to Address CHCI Conference
- Alibaba Prices IPO at $68 a Share
- Apple Locks Itself Out of Devices
- Veterans to Get Training as Solar Panel Installers
- Hispanics Doubt Marco Rubio's Chances
- Wildfires Rage in California
- John Cantlie Delivers ISIS Message to Save Life
- Alibaba: Today China, Tomorrow the World